Contacts: | Satya Kumar | Erica Rodriguez Pompen | ||||||
Investor Relations | Media Relations | |||||||
satyakumar@micron.com | epompen@micron.com | |||||||
(408) 450-6199 | (408) 834-1873 |
Quarterly Financial Results | |||||||||||||||||||||||
(in millions, except per share amounts) | GAAP(1) | Non-GAAP(2) | |||||||||||||||||||||
FQ4-24 | FQ3-24 | FQ4-23 | FQ4-24 | FQ3-24 | FQ4-23 | ||||||||||||||||||
Revenue | $ | 7,750 | $ | 6,811 | $ | 4,010 | $ | 7,750 | $ | 6,811 | $ | 4,010 | |||||||||||
Gross margin | 2,737 | 1,832 | (435) | 2,826 | 1,917 | (366) | |||||||||||||||||
percent of revenue | 35.3 | % | 26.9 | % | (10.8 | %) | 36.5 | % | 28.1 | % | (9.1 | %) | |||||||||||
Operating expenses | 1,215 | 1,113 | 1,037 | 1,081 | 976 | 842 | |||||||||||||||||
Operating income (loss) | 1,522 | 719 | (1,472) | 1,745 | 941 | (1,208) | |||||||||||||||||
percent of revenue | 19.6 | % | 10.6 | % | (36.7 | %) | 22.5 | % | 13.8 | % | (30.1 | %) | |||||||||||
Net income (loss) | 887 | 332 | (1,430) | 1,342 | 702 | (1,177) | |||||||||||||||||
Diluted earnings (loss) per share | 0.79 | 0.30 | (1.31) | 1.18 | 0.62 | (1.07) |
Annual Financial Results | |||||||||||||||||
(in millions, except per share amounts) | GAAP(1) | Non-GAAP(2) | |||||||||||||||
FY-24 | FY-23 | FY-24 | FY-23 | ||||||||||||||
Revenue | $ | 25,111 | $ | 15,540 | $ | 25,111 | $ | 15,540 | |||||||||
Gross margin | 5,613 | (1,416) | 5,943 | (1,196) | |||||||||||||
percent of revenue | 22.4 | % | (9.1 | %) | 23.7 | % | (7.7 | %) | |||||||||
Operating expenses | 4,309 | 4,329 | 4,008 | 3,623 | |||||||||||||
Operating income (loss) | 1,304 | (5,745) | 1,935 | (4,819) | |||||||||||||
percent of revenue | 5.2 | % | (37.0 | %) | 7.7 | % | (31.0 | %) | |||||||||
Net income (loss) | 778 | (5,833) | 1,472 | (4,862) | |||||||||||||
Diluted earnings (loss) per share | 0.70 | (5.34) | 1.30 | (4.45) |
FQ1-25 | GAAP(1) Outlook | Non-GAAP(2) Outlook | ||||||
Revenue | $8.70 billion ± $200 million | $8.70 billion ± $200 million | ||||||
Gross margin | 38.5% ± 1.0% | 39.5% ± 1.0% | ||||||
Operating expenses | $1.211 billion ± $15 million | $1.085 billion ± $15 million | ||||||
Diluted earnings per share | $1.54 ± $0.08 | $1.74 ± $0.08 |
4th Qtr. | 3rd Qtr. | 4th Qtr. | Year Ended | ||||||||||||||
August 29, 2024 | May 30, 2024 | August 31, 2023 | August 29, 2024 | August 31, 2023 | |||||||||||||
Revenue | $ | 7,750 | $ | 6,811 | $ | 4,010 | $ | 25,111 | $ | 15,540 | |||||||
Cost of goods sold | 5,013 | 4,979 | 4,445 | 19,498 | 16,956 | ||||||||||||
Gross margin | 2,737 | 1,832 | (435) | 5,613 | (1,416) | ||||||||||||
Research and development | 903 | 850 | 719 | 3,430 | 3,114 | ||||||||||||
Selling, general, and administrative | 295 | 291 | 219 | 1,129 | 920 | ||||||||||||
Restructure and asset impairments | 1 | — | 4 | 1 | 171 | ||||||||||||
Other operating (income) expense, net | 16 | (28) | 95 | (251) | 124 | ||||||||||||
Operating income (loss) | 1,522 | 719 | (1,472) | 1,304 | (5,745) | ||||||||||||
Interest income | 131 | 136 | 134 | 529 | 468 | ||||||||||||
Interest expense | (136) | (150) | (129) | (562) | (388) | ||||||||||||
Other non-operating income (expense), net | (7) | 10 | 9 | (31) | 7 | ||||||||||||
1,510 | 715 | (1,458) | 1,240 | (5,658) | |||||||||||||
Income tax (provision) benefit | (623) | (377) | 24 | (451) | (177) | ||||||||||||
Equity in net income (loss) of equity method investees | — | (6) | 4 | (11) | 2 | ||||||||||||
Net income (loss) | $ | 887 | $ | 332 | $ | (1,430) | $ | 778 | $ | (5,833) | |||||||
Earnings (loss) per share | |||||||||||||||||
Basic | $ | 0.80 | $ | 0.30 | $ | (1.31) | $ | 0.70 | $ | (5.34) | |||||||
Diluted | 0.79 | 0.30 | (1.31) | 0.70 | (5.34) | ||||||||||||
Number of shares used in per share calculations | |||||||||||||||||
Basic | 1,108 | 1,107 | 1,095 | 1,105 | 1,093 | ||||||||||||
Diluted | 1,125 | 1,123 | 1,095 | 1,118 | 1,093 |
As of | August 29, 2024 | May 30, 2024 | August 31, 2023 | ||||||||
Assets | |||||||||||
Cash and equivalents | $ | 7,041 | $ | 7,594 | $ | 8,577 | |||||
Short-term investments | 1,065 | 785 | 1,017 | ||||||||
Receivables | 6,615 | 5,131 | 2,443 | ||||||||
Inventories | 8,875 | 8,512 | 8,387 | ||||||||
Other current assets | 776 | 1,297 | 820 | ||||||||
Total current assets | 24,372 | 23,319 | 21,244 | ||||||||
Long-term marketable investments | 1,046 | 775 | 844 | ||||||||
Property, plant, and equipment | 39,749 | 37,926 | 37,928 | ||||||||
Operating lease right-of-use assets | 645 | 660 | 666 | ||||||||
Intangible assets | 416 | 413 | 404 | ||||||||
Deferred tax assets | 520 | 597 | 756 | ||||||||
Goodwill | 1,150 | 1,150 | 1,150 | ||||||||
Other noncurrent assets | 1,518 | 1,415 | 1,262 | ||||||||
Total assets | $ | 69,416 | $ | 66,255 | $ | 64,254 | |||||
Liabilities and equity | |||||||||||
Accounts payable and accrued expenses | $ | 7,299 | $ | 5,145 | $ | 3,958 | |||||
Current debt | 431 | 398 | 278 | ||||||||
Other current liabilities | 1,518 | 1,297 | 529 | ||||||||
Total current liabilities | 9,248 | 6,840 | 4,765 | ||||||||
Long-term debt | 12,966 | 12,860 | 13,052 | ||||||||
Noncurrent operating lease liabilities | 610 | 609 | 603 | ||||||||
Noncurrent unearned government incentives | 550 | 672 | 727 | ||||||||
Other noncurrent liabilities | 911 | 1,049 | 987 | ||||||||
Total liabilities | 24,285 | 22,030 | 20,134 | ||||||||
Commitments and contingencies | |||||||||||
Shareholders’ equity | |||||||||||
Common stock | 125 | 125 | 124 | ||||||||
Additional capital | 12,115 | 11,794 | 11,036 | ||||||||
Retained earnings | 40,877 | 40,169 | 40,824 | ||||||||
Treasury stock | (7,852) | (7,552) | (7,552) | ||||||||
Accumulated other comprehensive income (loss) | (134) | (311) | (312) | ||||||||
Total equity | 45,131 | 44,225 | 44,120 | ||||||||
Total liabilities and equity | $ | 69,416 | $ | 66,255 | $ | 64,254 | |||||
For the year ended | August 29, 2024 | August 31, 2023 | ||||||
Cash flows from operating activities | ||||||||
Net income (loss) | $ | 778 | $ | (5,833) | ||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
Depreciation expense and amortization of intangible assets | 7,780 | 7,756 | ||||||
Stock-based compensation | 833 | 596 | ||||||
Provision to write down inventories to net realizable value | — | 1,831 | ||||||
Goodwill impairment | — | 101 | ||||||
Change in operating assets and liabilities: | ||||||||
Receivables | (3,581) | 2,763 | ||||||
Inventories | (488) | (3,555) | ||||||
Accounts payable and accrued expenses | 1,915 | (1,302) | ||||||
Other current liabilities | 989 | (817) | ||||||
Other | 281 | 19 | ||||||
Net cash provided by operating activities | 8,507 | 1,559 | ||||||
Cash flows from investing activities | ||||||||
Expenditures for property, plant, and equipment | (8,386) | (7,676) | ||||||
Purchases of available-for-sale securities | (1,999) | (723) | ||||||
Proceeds from maturities and sales of available-for-sale securities | 1,794 | 1,591 | ||||||
Proceeds from government incentives | 315 | 710 | ||||||
Other | (33) | (93) | ||||||
Net cash provided by (used for) investing activities | (8,309) | (6,191) | ||||||
Cash flows from financing activities | ||||||||
Repayments of debt | (1,897) | (761) | ||||||
Payments of dividends to shareholders | (513) | (504) | ||||||
Repurchases of common stock - repurchase program | (300) | (425) | ||||||
Payments on equipment purchase contracts | (149) | (138) | ||||||
Proceeds from issuance of debt | 999 | 6,716 | ||||||
Other | 18 | 95 | ||||||
Net cash provided by (used for) financing activities | (1,842) | 4,983 | ||||||
Effect of changes in currency exchange rates on cash, cash equivalents, and restricted cash | 40 | (34) | ||||||
Net increase (decrease) in cash, cash equivalents, and restricted cash | (1,604) | 317 | ||||||
Cash, cash equivalents, and restricted cash at beginning of period | 8,656 | 8,339 | ||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 7,052 | $ | 8,656 |
4th Qtr. | 3rd Qtr. | 4th Qtr. | Year Ended | ||||||||||||||
August 29, 2024 | May 30, 2024 | August 31, 2023 | August 29, 2024 | August 31, 2023 | |||||||||||||
Provision to write down inventory to NRV | $ | — | $ | — | $ | — | $ | — | $ | (1,831) | |||||||
Lower costs from sale of inventory written down in prior periods | — | — | 563 | 987 | 844 | ||||||||||||
$ | — | $ | — | $ | 563 | $ | 987 | $ | (987) |
4th Qtr. | 3rd Qtr. | 4th Qtr. | Year Ended | ||||||||||||||
August 29, 2024 | May 30, 2024 | August 31, 2023 | August 29, 2024 | August 31, 2023 | |||||||||||||
GAAP gross margin | $ | 2,737 | $ | 1,832 | $ | (435) | $ | 5,613 | $ | (1,416) | |||||||
Stock-based compensation | 85 | 80 | 64 | 312 | 201 | ||||||||||||
Other | 4 | 5 | 5 | 18 | 19 | ||||||||||||
Non-GAAP gross margin | $ | 2,826 | $ | 1,917 | $ | (366) | $ | 5,943 | $ | (1,196) | |||||||
GAAP operating expenses | $ | 1,215 | $ | 1,113 | $ | 1,037 | $ | 4,309 | $ | 4,329 | |||||||
Stock-based compensation | (128) | (137) | (87) | (509) | (363) | ||||||||||||
Restructure and asset impairments | (1) | — | (4) | (1) | (171) | ||||||||||||
Patent cross-license agreement gain | — | — | — | 200 | — | ||||||||||||
Goodwill impairment | — | — | (101) | — | (101) | ||||||||||||
Litigation settlement | — | — | — | — | (68) | ||||||||||||
Other | (5) | — | (3) | 9 | (3) | ||||||||||||
Non-GAAP operating expenses | $ | 1,081 | $ | 976 | $ | 842 | $ | 4,008 | $ | 3,623 | |||||||
GAAP operating income (loss) | $ | 1,522 | $ | 719 | $ | (1,472) | $ | 1,304 | $ | (5,745) | |||||||
Stock-based compensation | 213 | 217 | 151 | 821 | 564 | ||||||||||||
Restructure and asset impairments | 1 | — | 4 | 1 | 171 | ||||||||||||
Patent cross-license agreement gain | — | — | — | (200) | — | ||||||||||||
Goodwill impairment | — | — | 101 | — | 101 | ||||||||||||
Litigation settlement | — | — | — | — | 68 | ||||||||||||
Other | 9 | 5 | 8 | 9 | 22 | ||||||||||||
Non-GAAP operating income (loss) | $ | 1,745 | $ | 941 | $ | (1,208) | $ | 1,935 | $ | (4,819) | |||||||
GAAP net income (loss) | $ | 887 | $ | 332 | $ | (1,430) | $ | 778 | $ | (5,833) | |||||||
Stock-based compensation | 213 | 217 | 151 | 821 | 564 | ||||||||||||
Restructure and asset impairments | 1 | — | 4 | 1 | 171 | ||||||||||||
Patent cross-license agreement gain | — | — | — | (200) | — | ||||||||||||
Goodwill impairment | — | — | 101 | — | 101 | ||||||||||||
Litigation settlement | — | — | — | — | 68 | ||||||||||||
Other | 5 | 3 | 7 | — | 32 | ||||||||||||
Estimated tax effects of above and other tax adjustments | 236 | 150 | (10) | 72 | 35 | ||||||||||||
Non-GAAP net income (loss) | $ | 1,342 | $ | 702 | $ | (1,177) | $ | 1,472 | $ | (4,862) | |||||||
GAAP weighted-average common shares outstanding - Diluted | 1,125 | 1,123 | 1,095 | 1,118 | 1,093 | ||||||||||||
Adjustment for stock-based compensation | 12 | 13 | — | 16 | — | ||||||||||||
Non-GAAP weighted-average common shares outstanding - Diluted | 1,137 | 1,136 | 1,095 | 1,134 | 1,093 | ||||||||||||
GAAP diluted earnings (loss) per share | $ | 0.79 | $ | 0.30 | $ | (1.31) | $ | 0.70 | $ | (5.34) | |||||||
Effects of the above adjustments | 0.39 | 0.32 | 0.24 | 0.60 | 0.89 | ||||||||||||
Non-GAAP diluted earnings (loss) per share | $ | 1.18 | $ | 0.62 | $ | (1.07) | $ | 1.30 | $ | (4.45) |
4th Qtr. | 3rd Qtr. | 4th Qtr. | Year Ended | ||||||||||||||
August 29, 2024 | May 30, 2024 | August 31, 2023 | August 29, 2024 | August 31, 2023 | |||||||||||||
GAAP net cash provided by operating activities | $ | 3,405 | $ | 2,482 | $ | 249 | $ | 8,507 | $ | 1,559 | |||||||
Expenditures for property, plant, and equipment | (3,120) | (2,086) | (1,461) | (8,386) | (7,676) | ||||||||||||
Payments on equipment purchase contracts | (22) | (45) | (26) | (149) | (138) | ||||||||||||
Proceeds from sales of property, plant, and equipment | 12 | 41 | 18 | 99 | 92 | ||||||||||||
Proceeds from government incentives | 48 | 33 | 462 | 315 | 710 | ||||||||||||
Investments in capital expenditures, net | (3,082) | (2,057) | (1,007) | (8,121) | (7,012) | ||||||||||||
Adjusted free cash flow | $ | 323 | $ | 425 | $ | (758) | $ | 386 | $ | (5,453) |
FQ1-25 | GAAP Outlook | Adjustments | Non-GAAP Outlook | ||||||||||||||||||||
Revenue | $8.70 billion ± $200 million | — | $8.70 billion ± $200 million | ||||||||||||||||||||
Gross margin | 38.5% ± 1.0% | 1.0% | A | 39.5% ± 1.0% | |||||||||||||||||||
Operating expenses | $1.211 billion ± $15 million | $126 million | B | $1.085 billion ± $15 million | |||||||||||||||||||
Diluted earnings per share(1) | $1.54 ± $0.08 | $0.20 | A, B, C | $1.74 ± $0.08 |
Non-GAAP Adjustments (in millions) | |||||||||||||||||||||||
A | Stock-based compensation – cost of goods sold | $ | 87 | ||||||||||||||||||||
A | Other – cost of goods sold | 4 | |||||||||||||||||||||
B | Stock-based compensation – research and development | 76 | |||||||||||||||||||||
B | Stock-based compensation – sales, general, and administrative | 50 | |||||||||||||||||||||
C | Tax effects of the above items and other tax adjustments | 3 | |||||||||||||||||||||
$ | 220 |